Weilan Wang

Weilan Wang

Auto-generated profile, based on publicly available information

Weilan Wang

Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025 in The Lancet Healthy Longevity
Verified
Journal Article
Open access
JLJessica K Lu
Jessica K Lu
WWWeilan Wang
Weilan Wang
MMMUHAMMAD DANIEL AZLAN MAHADZIR
MUHAMMAD DANIEL AZLAN MAHADZIR
JPJesse R. Poganik
Jesse R. Poganik
MMMahdi Moqri
Mahdi Moqri
Andrea Britta MaierAndrea Britta Maier
Andrea Britta Maier
Digital health technologies are transforming health care and personal health management by providing quantifiable data on physiological, behavioural, and environmental health parameters using digital biomarkers. This narrative review classified, characterised, and evaluated digital biomarkers of ageing across ten physiological systems to explore the applications of these biomarkers in research and clinical practice. The systematic search identified minimally invasive or non-invasively measured digital biomarkers suitable for longitudinal studies and practical use by community-dwelling adults. The digital biomarkers were classified according to their physiological system, characterised by their capture methods, and evaluated based on the following criteria: validity (age-associated, function-associated, and mortality-associated), generalisability, responsiveness to interventions, associations with clinical outcomes, and cost-effectiveness in large-scale settings. Digital biomarkers of ageing were found across eight physiological systems. Registered clinical trials that used these digital biomarkers as outcomes were also identified. Continued research and technological advancements are crucial for maximising the potential of digital biomarkers in promoting healthy ageing and longevity.

10 January 2021 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
JAJohn Adeoye
John Adeoye
AAAzeez Arisekola Alade
Azeez Arisekola Alade
WZWang‐Yong Zhu
Wang‐Yong Zhu
WWWeilan Wang
Weilan Wang
SCSiu Wai Choi
Siu Wai Choi
PTPeter Thomson
Peter Thomson

23 April 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
JTJian Hua Tay
Jian Hua Tay
YCYi Ern Chew
Yi Ern Chew
WWWeilan Wang
Weilan Wang
ZLZhi Meng Lim
Zhi Meng Lim
LGLihuan Guan
Lihuan Guan
Andrea Britta MaierAndrea Britta Maier
Andrea Britta Maier
This study aims to evaluate differences between Infinium MethylationEPIC (EPICv1) and Infinium MethylationEPICv2 (EPICv2) arrays in estimating DNAm age with eleven DNAm clocks using buffy coat, peripheral blood mononuclear cell (PBMC), and saliva from 16 healthy middle-aged individuals. DNAm ages were estimated using six principal component-based (PC) clocks (PCHorvath1, PCHorvath2, PCHannum, PCPhenoAge, PCGrimAge, and PCDNAmTL) and five non-PC clocks (DunedinPACE, DNAmFit, YingCausAge, YingAdaptAge, and YingDamAge) across all biological samples. Agreement between arrays was assessed using Spearman correlation, Bland-Altman plots, and Wilcoxon Signed-Rank test. The 16 individuals with median age of 48 [43.5;53.8] years, were predominantly female, Chinese and non-smokers. High correlations (ρ > 0.8) were observed between EPICv1 and EPICv2 except for DunedinPACE, YingDamAge and YingAdaptAge. PC-based clocks showed lower systematic bias (MAPE:0.118-8.98%) compared to non-PC-based clocks (MAPE:5.31-21.2%). Saliva samples demonstrated greatest variability between arrays. EPICv2 introduces systematic biases especially in non-PC-based clocks and between different biological samples.

20 December 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
TWTim Wehnes
Tim Wehnes
WWWeilan Wang
Weilan Wang
JTJian Hua Tay
Jian Hua Tay
LGLihuan Guan
Lihuan Guan
LFLei Feng
Lei Feng
Andrea Britta MaierAndrea Britta Maier
Andrea Britta Maier
Background: Biological age derived from DNA methylation (mAge) reflects aging-related physiological changes and the risk of age-related diseases. However, the association between oral microbiome and mAge remains unclear. Methods: We examined associations between mAge, physical and cognitive function, and the oral microbiome in 311 community-dwelling, predominantly Chinese adults aged 85 years or older. Oral microbial composition was assessed using 16S rRNA sequencing, and mAge was estimated using four established epigenetic clocks: HorvathAge, HannumAge, PhenoAge, and GrimAge. Results: In this cohort (median chronological age = 88.6 years; median DNA methylation–based biological age = 81.4 years), individuals with lower mAge deviation, corresponding to a younger biological age, exhibit lower oral microbial alpha diversity based on Simpson’s index. While no taxa differences reach significance after correction for multiple testing, several short-chain fatty acid–producing genera, such as Prevotella_7 and Veillonella, show nominal associations with both mAge deviation and methylation at aging-related CpG sites, particularly in neurologically relevant genes. Higher abundance of Prevotella_7 species is associated with better cognitive performance (Mini-Mental State Examination), whereas Alloprevotella is linked to poorer cognition. Conclusion: Our findings highlight that, as far as we aware, previously unrecognized oral microbiome composition links to lower mAge deviation and better cognitive function among the oldest-old, suggesting a potential role of the oral microbiome in promoting healthy aging and informing future mechanistic investigations.

3 April 2025 in APL Bioengineering
Verified
Journal Article
Open access
ZLZhiheng Lyu
Zhiheng Lyu
JYJiannan Yang
Jiannan Yang
ZXZhongzhi Xu
Zhongzhi Xu
WWWeilan Wang
Weilan Wang
WCWeibin Cheng
Weibin Cheng
QZQingpeng Zhang
Qingpeng Zhang
Current risk assessment models for predicting ischemic stroke (IS) in patients with atrial fibrillation (AF) often fail to account for the effects of medications and the complex interactions between drugs, proteins, and diseases. We developed an interpretable deep learning model, the AF-Biological-IS-Path (ABioSPath), to predict one-year IS risk in AF patients by integrating drug–protein–disease pathways with real-world clinical data. Using a heterogeneous multilayer network, ABioSPath identifies mechanisms of drug actions and the propagation of comorbid diseases. By combining mechanistic pathways with patient-specific characteristics, the model provides individualized IS risk assessments and identifies potential molecular pathways involved. We utilized the electronic health record data from 7859 AF patients, collected between January 2008 and December 2009 across 43 hospitals in Hong Kong. ABioSPath outperformed baseline models in all evaluation metrics, achieving an AUROC of 0.7815 (95% CI: 0.7346–0.8283), a positive predictive value of 0.430, a negative predictive value of 0.870, a sensitivity of 0.500, a specificity of 0.885, an average precision of 0.409, and a Brier score of 0.195. Cohort-level analysis identified key proteins, such as CRP, REN, and PTGS2, within the most common pathways. Individual-level analysis further highlighted the importance of PIK3/Akt and cytokine and chemokine signaling pathways and identified IS risks associated with less-studied drugs like prochlorperazine maleate. ABioSPath offers a robust, data-driven approach for IS risk prediction, requiring only routinely collected clinical data without the need for costly biomarkers. Beyond IS, the model has potential applications in screening risks for other diseases, enhancing patient care, and providing insights for drug development.